S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors

OncLive® On Air - En podcast av OncLive® On Air

Podcast artwork

Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.

Visit the podcast's native language site